Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 59

recruiting
3 987
countries
28
conditions
2 109

990 trials match your criteria

Peritoneal mesothelioma malignant+1

Not recruiting

Study on Talazoparib for Maintenance Treatment in Patients with Advanced Malignant Pleural or Peritoneal Mesothelioma After Initial Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Talazoparib

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Fenebrutinib and Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Demyelination

Not recruiting

Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab

Abdominal infection+3

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin Sulfate

Gastric cancer

Not recruiting

Study of hyperthermic intraperitoneal chemotherapy with oxaliplatin, fluorouracil, and calcium levofolinate in patients with advanced gastric cancer after surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

Non-small cell lung cancer

Not recruiting

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Patients with Severe Pulmonary Arterial Hypertension at High Risk of Mortality

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Squamous cell carcinoma of head and neck

Not recruiting

Study Comparing Radiotherapy Alone to Radiotherapy with Cisplatin for Patients with Sinus or Salivary Gland Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin

Hormone-refractory prostate cancer

Not recruiting

Study of Cabozantinib and Atezolizumab Compared to Hormonal Therapy in Adults with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Dermatomyositis

Not recruiting

Study on Baricitinib for Treating New-Onset Juvenile Dermatomyositis in Children

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.